MCID: PRV006
MIFTS: 55

Pervasive Developmental Disorder

Categories: Mental diseases

Aliases & Classifications for Pervasive Developmental Disorder

MalaCards integrated aliases for Pervasive Developmental Disorder:

Name: Pervasive Developmental Disorder 12 55 15
Pervasive Development Disorder 12 73
Pervasive Developmental Disorders 54
Autism Spectrum Disorders 73
Autistic Behavior 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0060040
ICD9CM 35 299.80
ICD10 33 F84

Summaries for Pervasive Developmental Disorder

NINDS : 54 The diagnostic category of pervasive developmental disorders (PDD) refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of onset is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns. Autism (a developmental brain disorder characterized by impaired social interaction and communication skills, and a limited range of activities and interests) is the most characteristic and best studied PDD. Other types of PDD include Asperger's Syndrome, Childhood Disintegrative Disorder, and Rett's Syndrome. Children with PDD vary widely in abilities, intelligence, and behaviors. Some children do not speak at all, others speak in limited phrases or conversations, and some have relatively normal language development. Repetitive play skills and limited social skills are generally evident. Unusual responses to sensory information, such as loud noises and lights, are also common.

MalaCards based summary : Pervasive Developmental Disorder, also known as pervasive development disorder, is related to childhood disintegrative disease and asperger syndrome, and has symptoms including sleep disturbances, photophobia and personality changes. An important gene associated with Pervasive Developmental Disorder is MECP2 (Methyl-CpG Binding Protein 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased viability after Maraba virus infection and Decreased viability after Maraba virus infection

Disease Ontology : 12 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors.

Wikipedia : 76 The diagnostic category pervasive developmental disorders (PDD), as opposed to specific developmental... more...

Related Diseases for Pervasive Developmental Disorder

Diseases related to Pervasive Developmental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Related Disease Score Top Affiliating Genes
1 childhood disintegrative disease 32.6 GABRB3 SHANK3
2 asperger syndrome 32.0 GABRB3 MECP2 NLGN3 NLGN4X SHANK3 SLC6A4
3 specific developmental disorder 31.9 FMR1 FOXP2 MECP2 SLC6A4
4 autism spectrum disorder 31.4 CHD8 CNTNAP2 FMR1 FOXP2 GABRB3 MECP2
5 atypical autism 31.3 NLGN3 NLGN4X
6 attention deficit-hyperactivity disorder 31.0 CNTNAP2 FMR1 MECP2 NLGN4X SLC6A4 SLC9A9
7 childhood apraxia of speech 30.9 CNTNAP2 FOXP2
8 alacrima, achalasia, and mental retardation syndrome 30.8 FMR1 MECP2 SHANK3
9 autism 29.5 CHD8 CNTNAP2 CTNND2 EIF4E FMR1 FOXP2
10 landau-kleffner syndrome 11.2
11 autism x-linked 1 11.1
12 autism x-linked 2 11.1
13 autism x-linked 3 11.1
14 autism x-linked 4 11.1
15 autism x-linked 5 11.1
16 autism x-linked 6 11.1
17 autism 15 11.1
18 autism 16 11.1
19 autism 17 11.1
20 autism 18 11.1
21 autism 5 11.0
22 autism 8 11.0
23 autism 3 11.0
24 autism 6 11.0
25 autism 7 11.0
26 autism 11 11.0
27 autism 12 11.0
28 potocki-lupski syndrome 11.0
29 autism 13 11.0
30 autism 9 11.0
31 autism 10 11.0
32 chromosome 16p11.2 deletion syndrome, 220-kb 10.8
33 autism 19 10.8
34 mental retardation, autosomal recessive 41 10.8
35 x-linked non-specific intellectual disability 10.8 MECP2 NLGN4X PTCHD1
36 rett syndrome 10.7
37 mutism 10.7 CNTNAP2 SHANK3
38 speech and communication disorders 10.5 CNTNAP2 FOXP2 MECP2 TOR3A
39 fragile x syndrome 10.4 EIF4E FMR1 MECP2 SLC6A4
40 psychotic disorder 10.3 GABRB3 SHANK3 SLC6A4
41 epilepsy 10.3
42 articulation disorder 10.2 CNTNAP2 FOXP2
43 anxiety 10.2
44 disease of mental health 10.2 FMR1 MECP2 SHANK3 SLC6A4 TOR3A
45 mental retardation, autosomal dominant 26 10.2
46 schizophrenia 10.2
47 aging 10.2
48 bipolar disorder 10.2
49 colitis 10.1
50 gilles de la tourette syndrome 10.0

Graphical network of the top 20 diseases related to Pervasive Developmental Disorder:



Diseases related to Pervasive Developmental Disorder

Symptoms & Phenotypes for Pervasive Developmental Disorder

UMLS symptoms related to Pervasive Developmental Disorder:


sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after Maraba virus infection GR00252-A-1 9.74 FOXP2 GABRB3 PTCHD1 SCT SHANK2 CHD8
2 Decreased viability after Maraba virus infection GR00252-A-2 9.74 FOXP2 GABRB3 PTCHD1 SCT SHANK2 CHD8
3 Decreased viability after Maraba virus infection GR00252-A-3 9.74 FOXP2

MGI Mouse Phenotypes related to Pervasive Developmental Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 CNTNAP2 CTNND2 FMR1 GABRB3 KCND2 MECP2
2 nervous system MP:0003631 9.36 MECP2 NLGN3 PTCHD1 SHANK2 SHANK3 SLC6A4

Drugs & Therapeutics for Pervasive Developmental Disorder

Drugs for Pervasive Developmental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
4
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 19982-08-2 4054
6
Guanfacine Approved, Investigational Phase 4,Not Applicable 29110-47-2 3519
7
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
8
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
9
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
10
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
11
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
12
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
13
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
14
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
15
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 73-31-4 896
16
Choline Approved, Nutraceutical Phase 4 62-49-7 305
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibodies Phase 4
23 gamma-Globulins Phase 4
24 Immunoglobulins Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Rho(D) Immune Globulin Phase 4
27 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antiviral Agents Phase 4,Phase 2
36 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
40 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
41 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Adrenergic Agonists Phase 4,Phase 2,Not Applicable
43 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Not Applicable
44 Adrenergic alpha-Agonists Phase 4,Phase 2,Not Applicable
45 Antihypertensive Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Atomoxetine Hydrochloride Phase 4,Phase 3
47 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
50 Antidotes Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 710)
# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
2 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
3 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
4 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
5 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
6 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
7 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
8 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
9 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
10 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
11 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
12 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
13 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
14 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
15 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
16 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
17 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Completed NCT01683565 Phase 4 LCPUFA oil supplement
18 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
19 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Enrolling by invitation NCT02940574 Phase 4 Syntocinon (Oxytocin)
20 Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enrolling by invitation NCT03333629 Phase 4
21 Improving Driving in Young People With Autism Spectrum Disorders Not yet recruiting NCT03538431 Phase 4 Buspirone
22 Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Not yet recruiting NCT03337646 Phase 4 Lisdexamfetamine Dimesylate
23 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4 Natrol
24 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
25 Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders Unknown status NCT02757066 Phase 2, Phase 3 NPC-15 Granules Lower Dose;NPC-15 Granules Higher Dose;NPC-15 Placebo Granule
26 Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls Unknown status NCT02568631 Phase 2, Phase 3
27 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
28 D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Completed NCT01086475 Phase 3 D-cycloserine;Placebo
29 Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3 Riluzole;placebo
30 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) Completed NCT00261508 Phase 3 risperidone
31 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
32 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
33 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
34 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00352352 Phase 3
35 Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder Completed NCT00352248 Phase 3
36 Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation Completed NCT00355329 Phase 3
37 Acamprosate in Youth With Fragile X Syndrome Completed NCT01300923 Phase 3 Acamprosate
38 Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders Completed NCT01021384 Phase 3
39 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
40 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
41 Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism Completed NCT01039792 Phase 2, Phase 3 Methyl B12
42 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER
43 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00337571 Phase 3 Aripiprazole;Placebo
44 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00332241 Phase 3 Aripiprazole;Placebo
45 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3 Galantamine
46 Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome Completed NCT01282268 Phase 3 arbaclofen;placebo
47 Pharmacogenomics in Autism Treatment Completed NCT00584701 Phase 2, Phase 3 Risperidone
48 Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children Completed NCT00178503 Phase 2, Phase 3 Methylphenidate-extended release;Methylphenidate-immediate release
49 Open Label Clinical Trial of Vitamin D in Children With Autism Completed NCT01535508 Phase 2, Phase 3 Liquid Vitamin D
50 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal

Search NIH Clinical Center for Pervasive Developmental Disorder

Genetic Tests for Pervasive Developmental Disorder

Anatomical Context for Pervasive Developmental Disorder

MalaCards organs/tissues related to Pervasive Developmental Disorder:

41
Brain, Testes, Eye, Bone, Heart, Liver, Cortex

Publications for Pervasive Developmental Disorder

Articles related to Pervasive Developmental Disorder:

(show top 50) (show all 272)
# Title Authors Year
1
Parental Alexithymia, Depression and Anxiety Levels of Children with Neurodevelopmental Disorders: A Comparative Study with Pervasive Developmental Disorders and ADHD. ( 29290095 )
2017
2
Neonatal factors among subjects diagnosed with a pervasive developmental disorder in the US. ( 28462601 )
2017
3
Autism Spectrum/Pervasive Developmental Disorder. ( 27262008 )
2016
4
Are There Differences in Neurocognition and Social Cognition Among Adolescents with Schizophrenia, a Pervasive Developmental Disorder, and Both Disorders? ( 27015370 )
2016
5
[Left temporal arachnoid cyst and specific learning disorders associated with Pervasive Developmental Disorders - Not Otherwise Specified (PDD-NOS): contributions of an integrative neuropsychomotor, neuropsychological, psychopathological and neurosurgical approach about a case report in a child (FranAsois)]. ( 27644917 )
2016
6
Hemispheric Processing of Idioms and Irony in Adults With and Without Pervasive Developmental Disorder. ( 26070277 )
2015
7
A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States. ( 26528457 )
2015
8
The Stability of Comorbid Psychiatric Disorders: A 7A Year Follow Up of Children with Pervasive Developmental Disorder-Not Otherwise Specified. ( 26456972 )
2015
9
Examining the criterion-related validity of the Pervasive Developmental Disorder Behavior Inventory. ( 24463433 )
2014
10
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( 24703761 )
2014
11
Psychiatric comorbidity in children with high-functioning pervasive developmental disorder. ( 25272562 )
2014
12
Detecting Subgroups in Children Diagnosed with Pervasive Developmental Disorder - Not Otherwise Specified. ( 25374133 )
2014
13
A comparison of DSM-IV pervasive developmental disorder and DSM-5 autism spectrum disorder prevalence in an epidemiologic sample. ( 24745950 )
2014
14
Sunsetting DSM-IV's pervasive developmental disorder. ( 24745948 )
2014
15
Psychological interventions in pervasive developmental disorder: An overview. ( 25788797 )
2014
16
Sensory hypersensitivity in children with high-functioning pervasive developmental disorder. ( 25803881 )
2014
17
A Case-Control Study Evaluating the Relationship Between Thimerosal-Containing Haemophilus influenzae Type b Vaccine Administration and the Risk for a Pervasive Developmental Disorder Diagnosis in the United States. ( 25382662 )
2014
18
Catatonic features in adolescents with schizophrenia with and without a comorbid pervasive developmental disorder. ( 24914405 )
2014
19
Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos: Comparative Observational Study and Literature Review. ( 24050746 )
2013
20
Brief report: An unusual manifestation of diagnostic overshadowing of pervasive developmental disorder--not otherwise specified: a five year longitudinal case study. ( 23108987 )
2013
21
Comparison of pervasive developmental disorder and schizophrenia by the Japanese version of the National Adult Reading Test. ( 22335467 )
2013
22
Psychiatric diagnostic screening of social maladaptive behaviour in children with mild intellectual disability: differentiating disordered attachment and pervasive developmental disorder behaviour. ( 23906477 )
2013
23
Reduced brain activation during imitation and observation of others in children with pervasive developmental disorder: a pilot study. ( 23718943 )
2013
24
Dual copy number variants involving 16p11 and 6q22 in a case of childhood apraxia of speech and pervasive developmental disorder. ( 22909776 )
2013
25
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. ( 23468071 )
2013
26
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. ( 24130822 )
2013
27
Inhibitory function and working memory in attention deficit/hyperactivity disorder and pervasive developmental disorders: does a continuous cognitive gradient explain ADHD and PDD traits? ( 24145729 )
2013
28
Pervasive developmental disorder in the children of immigrant parents: comparison of different assessment instruments. ( 24394875 )
2013
29
Anxiety in children with high-functioning pervasive developmental disorder. ( 23909078 )
2013
30
Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study. ( 23782127 )
2013
31
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. ( 23194148 )
2012
32
Global prevalence of autism and other pervasive developmental disorders. ( 22495912 )
2012
33
Sexual obsessions, compulsions, suicidality and homicidality in an adolescent diagnosed with bipolar disorder not otherwise specified, obsessive-compulsive disorder, pervasive developmental disorder not otherwise specified, and mild mental retardation. ( 22612525 )
2012
34
Executive function in children with pervasive developmental disorder and attention-deficit/hyperactivity disorder assessed by the Keio version of the Wisconsin card sorting test. ( 21917389 )
2012
35
A case of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) coexisting with pervasive developmental disorder harboring SCN1A mutation in addition to CHRNB2 mutation. ( 23032131 )
2012
36
Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. ( 23032385 )
2012
37
Is recovery from a pervasive developmental disorder possible? ( 22353321 )
2012
38
Is long-term prognosis for pervasive developmental disorder not otherwise specified different from prognosis for autistic disorder? Findings from a 30-year follow-up study. ( 21713590 )
2012
39
Using virtual reality environment to improve joint attention associated with pervasive developmental disorder. ( 22776822 )
2012
40
Novel AGTR2 missense mutation in a Japanese boy with severe mental retardation, pervasive developmental disorder, and epilepsy. ( 22269148 )
2012
41
Focal EEG abnormalities might reflect neuropathological characteristics of pervasive developmental disorder and attention-deficit/hyperactivity disorder. ( 22225922 )
2012
42
Impact of attention deficit hyperactivity disorder-like symptoms on the clinical features of adolescents with pervasive developmental disorders. ( 23857705 )
2012
43
Multi-channel near-infrared spectroscopy shows reduced activation in the prefrontal cortex during facial expression processing in pervasive developmental disorder. ( 22250607 )
2012
44
Brief report: prevalence of pervasive developmental disorder in Brazil: a pilot study. ( 21337063 )
2011
45
Possible evidence for a fall in the prevalence of high-functioning pervasive developmental disorder with age? ( 22937245 )
2011
46
Toward specifying pervasive developmental disorder-not otherwise specified. ( 21298812 )
2011
47
New onset of psychotic symptoms in an adolescent with pervasive developmental disorder, not otherwise specified. ( 21309699 )
2011
48
Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism. ( 22174567 )
2011
49
The specific impairment of fearful expression recognition and its atypical development in pervasive developmental disorder. ( 21919566 )
2011
50
Liquid melatonin via gastrostomy as an alternative hypnotic in a child with pervasive developmental disorder. ( 21663434 )
2011

Variations for Pervasive Developmental Disorder

Expression for Pervasive Developmental Disorder

Search GEO for disease gene expression data for Pervasive Developmental Disorder.

Pathways for Pervasive Developmental Disorder

Pathways related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.35 GABRB3 KCND2 NLGN3 NLGN4X SHANK2 SHANK3
2 11.63 CNTNAP2 FMR1 KCND2 MECP2 SHANK2 SHANK3
3
Show member pathways
11.57 NLGN3 NLGN4X SHANK2 SHANK3
4 11.49 GABRB3 KCND2 SLC6A4

GO Terms for Pervasive Developmental Disorder

Cellular components related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.89 FMR1 GABRB3 SHANK2 SHANK3 SLC6A4
2 synapse GO:0045202 9.85 FMR1 GABRB3 KCND2 NLGN3 NLGN4X SHANK2
3 dendritic spine GO:0043197 9.71 FMR1 KCND2 SHANK2 SHANK3
4 dendrite GO:0030425 9.7 CNTNAP2 CTNND2 FMR1 KCND2 NLGN4X SHANK2
5 postsynapse GO:0098794 9.69 FMR1 MECP2 NLGN3
6 postsynaptic density GO:0014069 9.65 FMR1 KCND2 NLGN4X SHANK2 SHANK3
7 perikaryon GO:0043204 9.62 CNTNAP2 CTNND2 FMR1 KCND2
8 mRNA cap binding complex GO:0005845 9.55 EIF4E FMR1
9 ionotropic glutamate receptor complex GO:0008328 9.54 SHANK2 SHANK3
10 neuron spine GO:0044309 9.52 SHANK2 SHANK3
11 spanning component of membrane GO:0089717 9.48 NLGN3 NLGN4X
12 asymmetric, glutamatergic, excitatory synapse GO:0098985 9.46 NLGN3 NLGN4X
13 symmetric, GABA-ergic, inhibitory synapse GO:0098983 9.43 NLGN3 NLGN4X
14 postsynaptic membrane GO:0045211 9.43 FMR1 GABRB3 KCND2 NLGN4X SHANK2 SHANK3
15 cell junction GO:0030054 9.28 CNTNAP2 CTNND2 FMR1 GABRB3 KCND2 NLGN3

Biological processes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.93 CHD8 CNTNAP2 MECP2 SCT SLC6A4
2 cerebellum development GO:0021549 9.77 FOXP2 MECP2 NLGN4X
3 synapse organization GO:0050808 9.75 CTNND2 NLGN3 NLGN4X
4 memory GO:0007613 9.73 MECP2 SHANK2 SHANK3 SLC6A4
5 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.72 NLGN3 SHANK2 SHANK3
6 synapse assembly GO:0007416 9.71 MECP2 NLGN3 SHANK2 SHANK3
7 positive regulation of excitatory postsynaptic potential GO:2000463 9.7 NLGN3 SHANK2 SHANK3
8 positive regulation of dendritic spine development GO:0060999 9.69 FMR1 SHANK2 SHANK3
9 regulation of AMPA receptor activity GO:2000311 9.67 NLGN3 SHANK2 SHANK3
10 long-term synaptic potentiation GO:0060291 9.67 MECP2 NLGN3 SHANK2 SHANK3
11 long term synaptic depression GO:0060292 9.66 SHANK2 SHANK3
12 neuron cell-cell adhesion GO:0007158 9.65 NLGN3 NLGN4X
13 regulation of dendritic spine morphogenesis GO:0061001 9.65 NLGN3 SHANK3
14 exploration behavior GO:0035640 9.65 SHANK2 SHANK3
15 brain morphogenesis GO:0048854 9.65 SHANK2 SHANK3 SLC6A4
16 adult behavior GO:0030534 9.65 CNTNAP2 NLGN3 NLGN4X SHANK2 SHANK3
17 thalamus development GO:0021794 9.64 CNTNAP2 PTCHD1
18 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.64 MECP2 NLGN3
19 presynaptic membrane assembly GO:0097105 9.63 NLGN3 NLGN4X
20 regulation of long-term synaptic potentiation GO:1900271 9.63 NLGN3 SHANK3
21 dendritic spine morphogenesis GO:0060997 9.63 CTNND2 SHANK2 SHANK3
22 learning GO:0007612 9.63 CNTNAP2 MECP2 NLGN3 NLGN4X SHANK2 SHANK3
23 presynapse assembly GO:0099054 9.62 NLGN3 NLGN4X
24 negative regulation of excitatory postsynaptic potential GO:0090394 9.62 NLGN3 NLGN4X
25 postsynaptic membrane assembly GO:0097104 9.61 NLGN3 NLGN4X
26 inhibitory postsynaptic potential GO:0060080 9.61 GABRB3 NLGN3
27 synaptic growth at neuromuscular junction GO:0051124 9.59 SHANK2 SHANK3
28 positive regulation of AMPA receptor activity GO:2000969 9.58 NLGN3 SHANK3
29 postsynaptic density assembly GO:0097107 9.57 SHANK2 SHANK3
30 multi-organism behavior GO:0051705 9.56 SHANK2 SHANK3
31 vocal learning GO:0042297 9.5 CNTNAP2 FOXP2 SHANK3
32 vocalization behavior GO:0071625 9.35 CNTNAP2 NLGN3 NLGN4X SHANK2 SHANK3
33 social behavior GO:0035176 9.23 CNTNAP2 MECP2 NLGN3 NLGN4X PTCHD1 SHANK2

Molecular functions related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor signaling complex scaffold activity GO:0030159 9.37 SHANK2 SHANK3
2 translation regulator activity GO:0045182 9.32 FMR1 RPL10
3 neurexin family protein binding GO:0042043 9.26 NLGN3 NLGN4X
4 siRNA binding GO:0035197 9.16 FMR1 MECP2
5 scaffold protein binding GO:0097110 9.13 NLGN3 NLGN4X SHANK3
6 GKAP/Homer scaffold activity GO:0030160 8.62 SHANK2 SHANK3

Sources for Pervasive Developmental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....